{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"title":"Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.6"}]}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.0"}]}],"title":"Week 28"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5"}]}],"title":"Week 32"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 40"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 44"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"}]}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 52"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 54"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"title":"Week 64"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 68"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 76"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 88"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}],"title":"Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 100"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 104"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 108"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 112"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 116"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 120"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 140"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 152"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 184"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 196"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 200"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4"}]}],"title":"Week 292"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"}]}],"title":"Week 296"}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"}],"units":"Participants"}],"description":"Participants who entered this study from study WA17824 on tocilizumab monotherapy, who did not achieve a 50% reduction in tender and swollen joint counts from Baseline of study WA17824, could add methotrexate or another allowable disease-modifying anti-rheumatic drug, according to the investigator's practice and as tolerated by the patient, at any time during this study.","groups":[{"description":"Participants received tocilizumab 8 mg/kg intravenously every 4 weeks till the end of the study (up to 7 years, 7 months). In addition, participants may have also received disease-modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs, and oral corticosteroids at the discretion of the investigator.","id":"OG000","title":"Tocilizumab"}],"paramType":"NUMBER","populationDescription":"All-exposure population: All participants who entered this study and received at least 1 dose of tocilizumab in either this extension study or in a core study. Only participants from the core study WA17824 are included in the analysis.","timeFrame":"Baseline to Week 296","title":"Percentage of Participants Who Changed From Monotherapy to Combination Therapy","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}